The Bridging Role Of Stereotactic Core Needle Biopsy in Individualized Treatment

https://my.clevelandclinic.org/health/diagnostics/24204-breast-biopsy-overview

Keywords:​ Stereotactic Core Needle Biopsy, Breast

Modern breast cancer treatment has long abandoned the "one-size-fits-all" model, ushering in an era of individualized precision medicine based on molecular subtyping and genomic profiling. Within this grand narrative, Stereotactic Core Needle Biopsy (SCNB) of the breast plays a pivotal role-it serves as the essential bridge connecting imaging discoveries to precise treatment. Without the high-quality tissue samples it provides, all subsequent genetic testing and targeted therapy decisions would be like water without a source or a tree without roots.

The value of SCNB extends far beyond simply "confirming benignancy or malignancy." The tissue cores it acquires-approximately 1–2 mm in diameter and 1–2 cm in length-contain a wealth of biological information. Pathologists can examine cellular atypia, mitotic figures, and lymphovascular invasion under the microscope to assign a histological grade (e.g., Nottingham grading). More importantly, this tissue can be utilized for a series of critical molecular assays:

1. Immunohistochemistry (IHC) Testing:​ Using specific antibodies, the expression levels of Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER2), and the proliferation index Ki-67 can be determined. These four markers form the basis of the internationally recognized molecular classification of breast cancer (Luminal A/B, HER2-overexpression, Triple-Negative) and directly dictate the applicability of endocrine therapy and anti-HER2 targeted therapy.
2. Fluorescence In SituHybridization (FISH) Testing:​ For cases with equivocal HER2 results (IHC 2+), FISH is required to confirm HER2 gene amplification. This is also the critical basis for deciding whether to use expensive targeted drugs such as trastuzumab.
3. Multi-Gene Expression Profile Analysis:​ Assays like Oncotype DX and MammaPrint analyze the expression levels of a panel of genes to quantitatively assess the recurrence risk in early-stage breast cancer patients, thereby guiding the need for chemotherapy. The tissue samples required for these assays are precisely derived from a successful SCNB procedure.

Therefore, a high-quality biopsy is equivalent to establishing a detailed "molecular profile" of the tumor. This profile guides the clinician in making the following decisions:

• Is neoadjuvant chemotherapy necessary?​ For HER2-positive or triple-negative breast cancers, preoperative chemotherapy (neoadjuvant therapy) can increase breast conservation rates and pathological complete response (pCR) rates. Biopsy results dictate the initiation of this strategy.
• Which endocrine drug is most effective?​ For patients with strongly ER-positive tumors, aromatase inhibitors may be superior to tamoxifen.
• Is there an opportunity for targeted therapy?​ HER2-positive patients are candidates for anti-HER2 treatment.
• What is the prognosis? Is intensified treatment needed?​ Patients with a high Ki-67 index generally have a poorer prognosis and may require more aggressive chemotherapy regimens.

It is worth noting that the quality of tissue obtained via SCNB is paramount. Insufficient sample volume, fragmented tissue, or crush artifact can compromise the accuracy of downstream assays. To mitigate this, the operating physician must select the appropriate gauge (e.g., 14G, 12G, or 10G) based on the lesion's size and characteristics, striving to acquire 3–5 satisfactory tissue cores. Concurrently, standardized protocols for specimen fixation, transport, and processing must be strictly followed to maximally preserve the integrity of DNA, RNA, and proteins.

In the chain of precision medicine, Stereotactic Core Needle Biopsy of the breast is both the starting point and the cornerstone. It translates imaging abnormalities that are "seen" into molecular information that can be "interpreted," enabling every breast cancer patient to receive a truly tailored treatment plan. This maximizes therapeutic efficacy while minimizing unnecessary toxicities. This technology is the crucial link that transforms laboratory research findings into tangible clinical benefits for patients at the bedside.